Advertisement

Establishment and proteomic characterization of a novel synovial sarcoma cell line, NCC-SS2-C1

  • Rieko Oyama
  • Fusako Kito
  • Marimu Sakumoto
  • Kumiko Shiozawa
  • Shunichi Toki
  • Makoto Endo
  • Akihiko Yoshida
  • Akira Kawai
  • Tadashi Kondo
Article

Abstract

Synovial sarcoma is an aggressive mesenchymal tumor, characterized by the presence of unique transfusion gene, SS18–SSX. Cell lines enable researchers to investigate the molecular backgrounds of disease and the significance of SS18–SSX in relevant cellular contexts. We report the establishment and proteomic characterization of a novel synovial sarcoma cell line. Primary tissue culture was performed using tumor tissue of synovial sarcoma. The established cell line was authenticated by assessing its DNA microsatellite short tandem repeat analysis and characterized by in vitro assay. Proteomic study was achieved by mass spectrometry, and the results were analyzed by treemap. The cell line NCC-SS2-C1 was established from a primary tumor tissue of a synovial sarcoma patient. The cell line has grown well for 11 mo and has been subcultured more than 15 times. The established cells were authenticated by assessing their short tandem repeat pattern comparing with that of original tumor tissue. The cells showed polygonal in shape and formed spheroid when seeded on the low-attachment dish. Proteomic analysis revealed the molecular pathways which are unique to the original tumor tissue or the established cell line. In conclusion, a novel synovial sarcoma cell line NCC-SS2-C1 was successfully established from the primary tumor tissue. The cell line has characteristic transfusion SS18–SSX and poses aggressive in vitro growth and capability of spheroid formation. Thus, NCC-SS2-C1 cell line will be a useful tool for investigation of the mechanisms of disease and the biological role of fusion gene.

Keywords

Synovial sarcoma Fusion gene Cell line Proteome 

Notes

Acknowledgements

We thank Drs. Y. Minami, K. Shimizu, T. Mori, T. Uehara, M. Sugawara, Y. Araki, and Ms. R. Nakano (Division of Musculoskeletal Oncology, National Cancer Center Hospital) for sampling tumor tissue specimens from surgically resected materials. We would also like to thank Editage (www.editage.jp) for English language editing and constructive comments on the manuscript.

Authors’ contributions

RO and TK prepared the manuscript. ST, ME, AY, and AK were involved in the analysis of the clinical and pathological data. RO, FK, MS, KS, and YT conducted the study. All authors read and approved the final manuscript.

Funding information

This work was supported by the National Cancer Center Research and Development Fund (26-A-3, 26-A-9, and 29-A-2). The funding body financially supported the research.

Compliance with ethical standards

Ethics approval and consent to participate

This study was approved by the ethical committee of the National Cancer Center, and the patient in this study provided written informed consent.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Supplementary material

11626_2018_237_MOESM1_ESM.xlsx (5.9 mb)
ESM 1 (XLSX 6055 kb)
11626_2018_237_MOESM2_ESM.xlsx (6.7 mb)
ESM 2 (XLSX 6829 kb)
11626_2018_237_MOESM3_ESM.xlsx (15 kb)
ESM 3 (XLSX 15 kb)

References

  1. Altermann E, Klaenhammer TR (2005) PathwayVoyager: pathway mapping using the Kyoto encyclopedia of genes and genomes (KEGG) database. BMC Genomics 6(1):60.  https://doi.org/10.1186/1471-2164-6-60 CrossRefPubMedPubMedCentralGoogle Scholar
  2. Barco R, Hunt LB, Frump AL, Garcia CB, Benesh A, Caldwell RL, Eid JE (2007) The synovial sarcoma SYT-SSX2 oncogene remodels the cytoskeleton through activation of the ephrin pathway. Mol Biol Cell 18(10):4003–4012.  https://doi.org/10.1091/mbc.E07-05-0496 CrossRefPubMedPubMedCentralGoogle Scholar
  3. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, Berger MF, Monahan JE, Morais P, Meltzer J, Korejwa A, Jane-Valbuena J, Mapa FA, Thibault J, Bric-Furlong E, Raman P, Shipway A, Engels IH, Cheng J, Yu GK, Yu J, Aspesi P Jr, de Silva M, Jagtap K, Jones MD, Wang L, Hatton C, Palescandolo E, Gupta S, Mahan S, Sougnez C, Onofrio RC, Liefeld T, MacConaill L, Winckler W, Reich M, Li N, Mesirov JP, Gabriel SB, Getz G, Ardlie K, Chan V, Myer VE, Weber BL, Porter J, Warmuth M, Finan P, Harris JL, Meyerson M, Golub TR, Morrissey MP, Sellers WR, Schlegel R, Garraway LA (2012) The cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483(7391):603–607.  https://doi.org/10.1038/nature11003 CrossRefPubMedPubMedCentralGoogle Scholar
  4. Billings SD, Meisner LF, Cummings OW, Tejada E (2000) Synovial sarcoma of the upper digestive tract: a report of two cases with demonstration of the X;18 translocation by fluorescence in situ hybridization. Mod Pathol 13(1):68–76.  https://doi.org/10.1038/modpathol.3880011 CrossRefPubMedGoogle Scholar
  5. Bozzi F, Ferrari A, Negri T, Conca E, Luca da R, Losa M, Casieri P, Orsenigo M, Lampis A, Meazza C, Casanova M, Pierotti MA, Tamborini E, Pilotti S (2008) Molecular characterization of synovial sarcoma in children and adolescents: evidence of Akt activation. Transl Oncol 1(2):95–101.  https://doi.org/10.1593/tlo.08121 CrossRefPubMedPubMedCentralGoogle Scholar
  6. Domcke S, Sinha R, Levine DA, Sander C, Schultz N (2013) Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 4:2126CrossRefPubMedPubMedCentralGoogle Scholar
  7. dos Santos NR, de Bruijn DR, van Kessel AG (2001) Molecular mechanisms underlying human synovial sarcoma development. Genes Chromosomes Cancer 30(1):1–14.  https://doi.org/10.1002/1098-2264(2000)9999:9999<::AID-GCC1056>3.0.CO;2-G CrossRefPubMedGoogle Scholar
  8. Eilber FC, Dry SM (2008) Diagnosis and management of synovial sarcoma. J Surg Oncol 97(4):314–320.  https://doi.org/10.1002/jso.20974 CrossRefPubMedGoogle Scholar
  9. Ertel A, Verghese A, Byers SW, Ochs M, Tozeren A (2006) Pathway-specific differences between tumor cell lines and normal and tumor tissue cells. Mol Cancer 5:55CrossRefPubMedPubMedCentralGoogle Scholar
  10. Falkenstern-Ge RF, Kimmich M, Grabner A, Horn H, Friedel G, Ott G, Kohlhaufl M (2014) Primary pulmonary synovial sarcoma: a rare primary pulmonary tumor. Lung 192:211–214CrossRefPubMedGoogle Scholar
  11. Ghadially FN (1987) Is synovial sarcoma a carcinosarcoma of connective tissue? Ultrastruct Pathol 11(2):147–151.  https://doi.org/10.3109/01913128709048320 CrossRefPubMedGoogle Scholar
  12. Gillet JP, Varma S, Gottesman MM (2013) The clinical relevance of cancer cell lines. J Natl Cancer Inst 105:452–458CrossRefPubMedPubMedCentralGoogle Scholar
  13. Herzog CE (2005) Overview of sarcomas in the adolescent and young adult population. J Pediatr Hematol Oncol 27(4):215–218.  https://doi.org/10.1097/01.mph.0000161762.53175.e4 CrossRefPubMedGoogle Scholar
  14. Hiraga H, Nojima T, Isu K, Yamashiro K, Yamawaki S, Nagashima K (1999) Histological and molecular evidence of synovial sarcoma of bone. A case report. J Bone Joint Surg Am 81(4):558–563.  https://doi.org/10.2106/00004623-199904000-00014 CrossRefPubMedGoogle Scholar
  15. Horvai AE, Kramer MJ, O'Donnell R (2006) Beta-catenin nuclear expression correlates with cyclin D1 expression in primary and metastatic synovial sarcoma: a tissue microarray study. Arch Pathol Lab Med 130(6):792–798. https://doi.org/10.1043/1543-2165(2006)130[792:CNECWC]2.0.CO;2Google Scholar
  16. Ishibe T, Nakayama T, Okamoto T, Aoyama T, Nishijo K, Shibata KR, Shima Y, Nagayama S, Katagiri T, Nakamura Y, Nakamura T, Toguchida J (2005) Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy. Clin Cancer Res 11(7):2702–2712.  https://doi.org/10.1158/1078-0432.CCR-04-2057 CrossRefPubMedGoogle Scholar
  17. Jaganathan S, Goyal A, Gadodia A, Rastogi S, Mittal R, Gamanagatti S (2012) Spectrum of synovial pathologies: a pictorial assay. Curr Probl Diagn Radiol 41(1):30–42.  https://doi.org/10.1067/j.cpradiol.2011.07.002 CrossRefPubMedGoogle Scholar
  18. Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR (2013) SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas. Oncogene 32:2365–2371 2375.e2361–2365CrossRefPubMedGoogle Scholar
  19. Kondo T, Hirohashi S (2007) Application of highly sensitive fluorescent dyes (CyDye DIGE Fluor saturation dyes) to laser microdissection and two-dimensional difference gel electrophoresis (2D-DIGE) for cancer proteomics. Nat Protoc 1(6):2940–2956.  https://doi.org/10.1038/nprot.2006.421 CrossRefGoogle Scholar
  20. Ladanyi M (2001) Fusions of the SYT and SSX genes in synovial sarcoma. Oncogene 20(40):5755–5762.  https://doi.org/10.1038/sj.onc.1204601 CrossRefPubMedGoogle Scholar
  21. Ladanyi M, Antonescu CR, Leung DH, Woodruff JM, Kawai A, Healey JH, Brennan MF, Bridge JA, Neff JR, Barr FG, Goldsmith JD, Brooks JS, Goldblum JR, Ali SZ, Shipley J, Cooper CS, Fisher C, Skytting B, Larsson O (2002) Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62(1):135–140PubMedGoogle Scholar
  22. Mancuso T, Mezzelani A, Riva C, Fabbri A, Dal Bo L, Sampietro G, Perego P, Casali P, Zunino F, Sozzi G, Pierotti MA, Pilotti S (2000) Analysis of SYT-SSX fusion transcripts and bcl-2 expression and phosphorylation status in synovial sarcoma. Lab Investig 80(6):805–813.  https://doi.org/10.1038/labinvest.3780085 CrossRefPubMedGoogle Scholar
  23. Pretto D, Barco R, Rivera J, Neel N, Gustavson MD, Eid JE (2006) The synovial sarcoma translocation protein SYT-SSX2 recruits beta-catenin to the nucleus and associates with it in an active complex. Oncogene 25(26):3661–3669.  https://doi.org/10.1038/sj.onc.1209413 CrossRefPubMedGoogle Scholar
  24. Raney RB (2005) Synovial sarcoma in young people: background, prognostic factors, and therapeutic questions. J Pediatr Hematol Oncol 27(4):207–211.  https://doi.org/10.1097/01.mph.0000161764.60798.60 CrossRefPubMedGoogle Scholar
  25. Rees MG, Seashore-Ludlow B, Cheah JH, Adams DJ, Price EV, Gill S, Javaid S, Coletti ME, Jones VL, Bodycombe NE, Soule CK, Alexander B, Li A, Montgomery P, Kotz JD, Hon CS, Munoz B, Liefeld T, Dancik V, Haber DA, Clish CB, Bittker JA, Palmer M, Wagner BK, Clemons PA, Shamji AF, Schreiber SL (2016) Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat Chem Biol 12(2):109–116.  https://doi.org/10.1038/nchembio.1986 CrossRefPubMedGoogle Scholar
  26. Ren T, Lu Q, Guo W, Lou Z, Peng X, Jiao G, Sun Y (2013) The clinical implication of SS18-SSX fusion gene in synovial sarcoma. Br J Cancer 109(8):2279–2285.  https://doi.org/10.1038/bjc.2013.547 CrossRefPubMedPubMedCentralGoogle Scholar
  27. Sakumoto M, Takahashi M, Oyama R, Takai Y, Kito F, Shiozawa K, Qiao Z, Yoshida A, Endo M, Kawai A, Kondo T (2017) Establishment and proteomic characterization of NCC-LMS1-C1, a novel cell line of primary leiomyosarcoma in the bone. Jpn J Clin Oncol 47(10):954–961.  https://doi.org/10.1093/jjco/hyx096 CrossRefPubMedGoogle Scholar
  28. Schoolmeester JK, Cheville JC, Folpe AL (2014) Synovial sarcoma of the kidney: a clinicopathologic, immunohistochemical, and molecular genetic study of 16 cases. Am J Surg Pathol 38(1):60–65.  https://doi.org/10.1097/PAS.0b013e31829b2d0d CrossRefPubMedGoogle Scholar
  29. Siehl JM, Thiel E, Schmittel A, Hutter G, Deckert PM, Szelenyi H, Keilholz U (2005) Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study. Cancer 104:611–617CrossRefPubMedGoogle Scholar
  30. Smith ME, Fisher C, Wilkinson LS, Edwards JC (1995) Synovial sarcoma lack synovial differentiation. Histopathology 26(3):279–281.  https://doi.org/10.1111/j.1365-2559.1995.tb01444.x CrossRefPubMedGoogle Scholar
  31. Spillane AJ, A’Hern R, Judson IR, Fisher C, Thomas JM (2000) Synovial sarcoma: a clinicopathologic, staging, and prognostic assessment. J Clin Oncol 18:3794–3803CrossRefPubMedGoogle Scholar
  32. Spira AI, Ettinger DS (2002) The use of chemotherapy in soft-tissue sarcomas. Oncologist 7(4):348–359.  https://doi.org/10.1634/theoncologist.7-4-348 CrossRefPubMedGoogle Scholar
  33. Sun B, Sun Y, Wang J, Zhao X, Wang X, Hao X (2006) Extent, relationship and prognostic significance of apoptosis and cell proliferation in synovial sarcoma. Eur J Cancer Prev 15(3):258–265.  https://doi.org/10.1097/01.cej.0000198896.02185.68 CrossRefPubMedGoogle Scholar
  34. Tyanova S, Albrechtsen R, Kronqvist P, Cox J, Mann M, Geiger T (2016) Proteomic maps of breast cancer subtypes. Nat Commun 7:10259.  https://doi.org/10.1038/ncomms10259 CrossRefPubMedPubMedCentralGoogle Scholar
  35. Wang JG, Li NN (2013) Primary cardiac synovial sarcoma. Ann Thorac Surg 95(6):2202–2209.  https://doi.org/10.1016/j.athoracsur.2013.01.030 CrossRefPubMedGoogle Scholar
  36. Weiss (2013) Enzinger and Weiss’s soft tissue tumors. Mosby Inc., St. LouisGoogle Scholar
  37. Wisniewski JR, Zougman A, Nagaraj N, Mann M (2009) Universal sample preparation method for proteome analysis. Nat Methods 6(5):359–362.  https://doi.org/10.1038/nmeth.1322 CrossRefPubMedGoogle Scholar
  38. Zagars GK, Ballo MT, Pisters PW, Pollock RE, Patel SR, Benjamin RS, Evans HL (2003) Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy: an analysis of 1225 patients. Cancer 97(10):2530–2543.  https://doi.org/10.1002/cncr.11365 CrossRefPubMedGoogle Scholar

Copyright information

© The Society for In Vitro Biology 2018

Authors and Affiliations

  1. 1.Department of Innovative Seeds EvaluationNational Cancer Center Research InstituteChuo-kuJapan
  2. 2.Division of Rare Cancer ResearchNational Cancer Center Research InstituteChuo-kuJapan
  3. 3.Division of Musculoskeletal OncologyNational Cancer Center HospitalChuo-kuJapan
  4. 4.Department of Pathology and Clinical LaboratoriesNational Cancer Center HospitalChuo-kuJapan

Personalised recommendations